Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

June 26, 2025 — Medicover Genetics was recently profiled in GenomeWeb for its pioneering work in minimal residual disease (MRD) diagnostics. The article covers our presentation at the 2025 ASCO Annual Meeting, where we shared early results from the DART trial in collaboration with Oslo University Hospital.

Our MRD platform, developed entirely in-house, utilizes a hybrid capture-based liquid biopsy to detect circulating tumor DNA (ctDNA) across a 293-gene panel. The test is designed to support real-time, non-invasive monitoring of cancer progression and response to treatment.

“The initial results were very promising,” said Dr. Stefan Christoph Mehrle, Head of Business Unit Genetics. “With relatively few players in Europe developing MRD or liquid biopsy in general we were in a good position to take this on and tailor it to European needs.”

In the DART trial, our assay achieved a 92 percent baseline ctDNA detection rate. Early findings suggest that the presence of ctDNA during treatment may be a significant predictor of progression-free and overall survival, pointing to its potential as a molecular biomarker for guiding therapy decisions.

This recognition by GenomeWeb affirms our commitment to enabling more precise, data-driven oncology care through robust, scalable diagnostics.

Read the full article on (subscription required).

Last updated: October 8, 2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?